Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25063211 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Alaina C Larson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 6819…. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Pancreatic cancer is a lethal disease, harboring a five-year overall survival rate of only 13%. Current treatment approaches thus require modulation, with attention shifting towards liberating the stalled efficacy of immunotherapies. Select chemotherapy drugs which possess inherent immune-modifying behaviors could revitalize immune activity against pancreatic tumors and potentiate immunotherapeutic success. In this study, we characterized the influence of gemcitabine, a chemotherapy drug approved for the treatment of pancreatic cancer, on tumor antigen presentation by human leukocyte antigen class I (HLA-I). Gemcitabine increased pancreatic cancer cells’ HLA-I mRNA transcripts, total protein, surface expression, and surface stability. Temperature-dependent assay results indicated that the increased HLA-I stability may be due to reduced binding of low affinity peptides. Mass spectrometry analysis confirmed changes in the HLA-I-presented peptide pool post-treatment, and computational predictions suggested improved affinity and immunogenicity of peptides displayed solely by gemcitabine-treated cells. Most of the gemcitabine-exclusive peptides were derived from unique source proteins, with a notable overrepresentation of translation-related proteins. Gemcitabine also increased expression of select immunoproteasome subunits, providing a plausible mechanism for its modulation of the HLA-I-bound peptidome. Our work supports continued investigation of immunotherapies, including peptide-based vaccines, to be used with gemcitabine as new combination treatment modalities for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eppley Institute for Research in Cancer & Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Departments of Psychology and Biology, University of Nebraska Omaha, Omaha, NE 68192, USA.
ORCID-Profile: Gabrielle L Brumfield
Förderung
- NIGMS NIH HHS
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
- American Association of Immunologists Careers in Immunology Fellowship Program for Computational Scientists and Immunologists
- National Institutes of Health-funded Cancer Biology Training Program
- Graduate Studies Office Fellowship Program
- National Cancer Institute Youth Enjoy Science Research Education Program
Zitieren
APA
Larson, A. C., Knoche, S. M., Brumfield, G. L., Doty, K. R., Gephart, B. D., Moore-Saufley, P. R., & Solheim, J. C. (2024). Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063211
Vancouver
Larson AC, Knoche SM, Brumfield GL, Doty KR, Gephart BD, Moore-Saufley PR, et al. Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063211
BibTeX
@article{Larson2024,
author = {Larson, Alaina C and Knoche, Shelby M and Brumfield, Gabrielle L and Doty, Kenadie R and Gephart, Benjamin D and Moore-Saufley, Promise R and Solheim, Joyce C},
title = {Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25063211}
}
EUVIMED